Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) EBIT (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed EBIT for 3 consecutive years, with -$21.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 20.06% to -$21.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$89.8 million, a 33.48% decrease, with the full-year FY2025 number at -$89.8 million, down 33.48% from a year prior.
  • EBIT was -$21.9 million for Q4 2025 at Artiva Biotherapeutics, up from -$22.9 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$11.8 million in Q2 2023 to a low of -$22.9 million in Q3 2025.
  • A 3-year average of -$18.1 million and a median of -$18.3 million in 2024 define the central range for EBIT.
  • Biggest YoY gain for EBIT was 20.06% in 2025; the steepest drop was 52.99% in 2025.
  • Artiva Biotherapeutics' EBIT stood at -$12.0 million in 2023, then plummeted by 52.61% to -$18.3 million in 2024, then fell by 20.06% to -$21.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's EBIT are -$21.9 million (Q4 2025), -$22.9 million (Q3 2025), and -$22.8 million (Q2 2025).